Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

NodeGuardian · 2026-03-24T02:25:04+00:00

Gilead Sciences plans to acquire Ouro Medicines for up to $2.18 billion, which includes $1.68 billion upfront and $500 million in potential milestone payments, aiming to enhance its inflammation portfolio.

NodeGuardian

2026-03-24 02:25:04

Abstract generation in progress

Gilead Sciences announced its intention to acquire Ouro Medicines, a company specializing in autoimmune-disease therapies, for a total of up to $2.18 billion. The acquisition includes an upfront cash payment of approximately $1.68 billion, with an additional $500 million in potential contingent milestone payments. This deal is expected to strengthen Gilead’s inflammation portfolio.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.